Latest News | Torrent Pharma Inks Licensing Pact with Zydus for Liver Disease Drug

New Delhi, Nov 10 (PTI) Torrent Pharmaceuticals on Friday said it has inked a licensing agreement with Zydus Lifesciences to co-market a product for the treatment of non-alcoholic steato hepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

As per the agreement, the companies will co-market Saroglitazar Mg in the country.

Also Read | Diwali Muhurat Trading 2023 Date, Time: All You Need To Know About Special One-Hour Trading Session of Stock Market To Be Held on Deepavali.

Under the terms of this agreement, Torrent will have semi-exclusive rights to co-market the product in India under the brand name Vorxar, Torrent said in a statement.

Zydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them.

Also Read | Pippa Actress Mrunal Thakur Opens Up on Delay of Ishaan Khattar-Starrer: 'A Film Like My Baby Deserves its Time to Shine'.

Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones, it noted.

As the only approved drug for NASH and NAFLD in the country, Saroglitazar Magnesium is likely to play a key role in managing and mitigating these progressive and prevalent liver disorders.

Currently, there is no approved drug for the treatment of NASH and NAFLD anywhere else in the world.

Torrent Pharmaceuticals Director Aman Mehta said the pact would help augment its gastroenterology franchise.

Zydus Lifesciences Managing Director Sharvil Patel said the association with Torrent is testament to our long-term vision of expanding the reach of the drug.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)